Patient Square Capital LP

Search
⚲

Patient Square Capital LP ✚
CRD #	312203
SEC #	801-120508
CIK #	0001819257, 0001827614
AUM	17.51 B (2026-05-26)
Employees	97 (52% Investors, 3% Brokers)
Fees
Minimum
Phone	650-677-8100
Address	2884 Sand Hill Road Menlo Park, CA 94025
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($B) Copy

In the News
Wed, 24 Jun 2026	Osanni Bio closes $190M Series B led by Patient Square Capital — Dealroom
Wed, 06 May 2026	Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor — Business Wire
Wed, 06 May 2026	Patient Square Capital Names Timothy P. Walbert Senior Advisor — citybiz

Sector	Form 13F Holdings	Value ($M)
	Roivant Sciences Ltd	226.2
	Argenx SE	26.8
	Insmed Inc	25.8
	BeiGene Ltd	23.9
	UNUM Therapeutics Inc	22.9
	Mirum Pharmaceuticals Inc	21.2
	Belite Bio Inc	18.6
	Legend Biotech Corp	17.9
	Nektar Therapeutics	15.1
	DBV Technologies Sa	14.5
View All

Holdings by Sector ($M)

Type	Form D Funds	Date	Sold	AUM
PE	27 Patient Square Paradigm Coinvest LP	[2026-03-31]		500.0 M
	Filed 2025-02-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	28 Patient Square Premium Coinvest LP	[2026-03-31]		50.0 M
	Filed 2025-11-14 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	29 Blackwell Capital Partners II LP	[2026-03-31]		1,517.6 M
	Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	30 Redwood Capital Discretionary Partners LP	[2026-03-31]		13.8 M
	Filed 2025-08-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	20 Patient Square Equity Executives II LP	2025-03-26
PE	21 Patient Square Equity Executives QP II LP	[2025-03-26]
	Filed 2026-03-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	22 Patient Square Equity Partners II LP	[2025-03-26]	3,111.0 M	1,510.7 M
	Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	23 Patient Square Equity Partners II-A LP	[2025-03-26]	3,111.0 M	1,510.7 M
	Filed 2025-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	24 Patient Square Equity Partners II-B LP	2025-03-26		297.6 M
PE	25 Patient Square Equity Co-Invest II LP	[2025-03-26]	61.2 M	61.2 M
	Filed 2025-11-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	26 Patient Square Compass Coinvest LP	[2025-03-26]	15.0 M	170.4 M
	Filed 2025-01-27 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	05 Blackwell Capital Partners LP	[2024-03-29]		2,082.0 M
	Filed 2023-04-27 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	07 PSC Atlantic Coinvest LP	[2024-03-29]		110.6 M
	Filed 2023-07-19 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	08 PSC Condor Coinvest LP	[2024-03-29]		213.5 M
	Filed 2023-01-30 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	11 PSC EP Discretionary Coinvest III LP	[2024-03-29]		570.9 M
	Filed 2023-01-30 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	12 PSC Ginger Coinvest II LP	[2024-03-29]		59.0 M
	Filed 2023-07-05 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	19 PSC Stanley Coinvest LP	[2024-03-29]		965.1 M
	Filed 2023-07-19 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	10 PSC EP Discretionary Coinvest II LP	[2023-03-30]		342.1 M
	Filed 2022-10-11 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	13 PSC Hero Coinvest LP	[2023-03-30]		390.4 M
	Filed 2022-09-30 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	14 PSC KR Coinvest LP	[2023-03-30]	140.0 M	386.6 M
	Filed 2023-05-09 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	15 PSC Spark Coinvest LP	[2023-03-30]		99.1 M
	Filed 2022-06-02 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	18 PSC Sperry Coinvest IV LP	[2023-03-30]		75.2 M
	Filed 2022-10-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	PSC Ginger Coinvest LP	[2023-03-30]		0.0 M
	Filed 2022-10-13 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	PSC Sperry Coinvest III LP	[2023-03-30]		0.2 M
	Filed 2022-08-10 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	16 PSC Sperry Coinvest LP	[2022-03-31]		110.1 M
	Filed 2021-11-23 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	17 PSC Sperry Coinvest II LP	[2022-03-31]		5.3 M
	Filed 2021-11-24 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	09 PSC EP Discretionary Coinvest LP	[2021-10-11]		204.3 M
	Filed 2021-10-05 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	01 Patient Square Equity Executives QP LP	[2021-07-12]	78.0 M	141.2 M
	Filed 2022-06-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	02 Patient Square Equity Executives LP	[2021-07-12]	78.0 M	6.6 M
	Filed 2022-06-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	06 Patient Square Atlantic LP	[2021-07-12]		61.9 M
	Filed 2021-06-07 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
PE	03 Patient Square Equity Partners LP	[2021-02-10]	2,625.0 M	2,982.0 M
	Filed 2022-06-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
PE	04 Patient Square Equity Partners-A LP	[2021-02-10]	2,625.0 M	2,784.1 M
	Filed 2022-06-22 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose

AUM Breakdown	Accounts	AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	30	17.5
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	30	17.5
By Discretionary
Discretionary	30	17.5
Non-Discretionary	0	0.0
Total	30	17.5
By Non-United States Persons
Non-United States Persons		6.9
United States Persons		10.7
Total	30	17.5

Form D Directors	Role	# Filings	# Firms
James Momtazee	Executive Officer	44	3
Adam Fliss	Executive Officer	35	2
Maria Walker	Executive Officer	24	2
Carolyn Drayer-Greenwalt	Executive Officer	4	1

EDGAR Form	CIK	2011 - 2026
13F-HR	[0001819257]
3	[0001827614]
4	[0001827614]
SC 13G	[0001827614]

Form 13D/13G Filer	Form 13D/13G Subject	Filed
Patient Square Capital LLC	Montes Archimedes Acquisition Corp	[2021-02-11]

Firm Profile (Form ADV)
Serves	Institutional
Fund Types	Private Equity

Form 3/4/5 Subject	2011 - 2026
Montes Archimedes Acquisition Corp
Patient Square Capital LLC

Insider Transaction (Form 3/4/5)	Date	Action	Shares	Price	Value ($)
Montes Archimedes Acquisition Corp MAAC Class B common stock · derivative	2021-09-30	Grant	10,167,956
Montes Archimedes Acquisition Corp MAAC Class B common stock · derivative	2020-11-20	Other	1,232,044

Comparable Firms	State	AUM
American Securities LLC ✚	NY	18.91 B
Monroe Capital Management Advisors LLC ✚	IL	18.56 B
1823 Partners US LLC ✚	FL	18.53 B
Arctos Partners LP ✚	TX	18.22 B
RCP Advisors 2 LLC ✚	TX	18.21 B
Arlington Management Employees LLC ✚	MD	18.19 B
Atlas FRM LLC ✚	CT	18.12 B
Invesco Loan Manager LLC ✚	NY	17.69 B
Searchlight Capital Partners LP ✚	NY	17.51 B
Niobrara Capital Partners LP ✚	NY	17.07 B

Patient Square Capital LP

Assets, Funds, Holdings